Format

Send to

Choose Destination
Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 Oct 25.

Dendritic Cells and Cancer Immunity.

Author information

1
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL, USA.
2
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Brian.Ruffell@moffitt.org.

Abstract

Dendritic cells (DCs) are central regulators of the adaptive immune response, and as such are necessary for T-cell-mediated cancer immunity. In particular, antitumoral responses depend on a specialized subset of conventional DCs that transport tumor antigens to draining lymph nodes and cross-present antigen to activate cytotoxic T lymphocytes. DC maturation is necessary to provide costimulatory signals to T cells, but while DC maturation occurs within tumors, it is often insufficient to induce potent immunity, particularly in light of suppressive mechanisms within tumors. Bypassing suppressive pathways or directly activating DCs can unleash a T-cell response, and although clinical efficacy has proven elusive, therapeutic targeting of DCs continues to hold translational potential in combinatorial approaches.

KEYWORDS:

antigen presentation; cancer; dendritic cells; immunotherapy; tumor microenvironment; vaccination

PMID:
27793569
PMCID:
PMC5135568
DOI:
10.1016/j.it.2016.09.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center